Chidamide for Patients With Relapse or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
Status:
Unknown status
Trial end date:
2020-09-30
Target enrollment:
Participant gender:
Summary
Study of Chidamide as a single-agent treatment for patients with relapse or refractory
Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)